Please login to the form below

Not currently logged in
Email:
Password:

Sanofi and Regeneron ramp up immuno-oncology collaboration

Will put an additional $1bn in investigational candidate cemiplimab

Sanofi

Sanofi and Regeneron are set to give the development programme for their immuno-oncology candidate cemiplimab a $1bn boost.

The PD1 antibody is the ‘backbone’ of Sanofi’s checkpoint immuno-oncology strategy and a first regulatory submission - to the US FDA for cutaneous squamous cell carcinoma - is expected before April.

Sanofi and Regeneron’s investment in the drug will be increased to $1.64bn, almost a $1bn surge on their initial agreement back in 2015, and the companies said they would also equally fund the development of cemiplimab.

Additionally, the companies claimed they would be continuing its investment in other immuno-oncology programmes under its existing agreement.

Elias Zerhouni, MD, global head of R&D at Sanofi, said: “The ongoing collaboration between Sanofi and Regeneron underscores our commitment to partnering in the development of medicines to treat significant unmet medical needs.”

Meanwhile, the companies have also said they will provide an additional investment in the dupilumab development programme - for type 2 allergic diseases.

Zerhouni added: “The expansion of these clinical programmes, for both cemiplimab and dupilumab should enable us to quickly identify treatment opportunities in other disease areas.”

The injection of funds is intended to help accelerate planned new studies in chronic obstructive pulmonary disease (COPD), peanut allergy and grass allergy, as well as in patients who have multiple allergic conditions.

Finally, there will also be more money to accelerate and expand the development of the firms’ IL-33 antibody REGN3500, with studies expected to be conducted in atopic dermatitis, asthma and COPD.

Article by
Gemma Jones

9th January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics